Company news
Supernus Pharmaceuticals, Inc. news in 2024
Supernus Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 25, 2024
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
November 12, 2024
Supernus Announces Third Quarter 2024 Financial Results
November 3, 2024
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
October 30, 2024
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
October 20, 2024
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
October 16, 2024
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
October 9, 2024
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
September 23, 2024
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 18, 2024
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 27, 2024
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
August 18, 2024
Supernus Announces Second Quarter 2024 Financial Results
August 5, 2024
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
July 31, 2024
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 22, 2024
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 22, 2024
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 8, 2024
Supernus Announces First Quarter 2024 Financial Results
May 7, 2024
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
April 30, 2024
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 23, 2024
Supernus Provides Regulatory Update for SPN-830
April 7, 2024
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 12, 2024
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 4, 2024
Calls in 2024
- Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2024 Earnings Call
Nov 4, 2024
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2024 Earnings Call
Aug 6, 2024
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2024 Earnings Call
May 8, 2024
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2023 Earnings Call
Feb 27, 2024
Transcript